Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Allergy and Asthma Reports
Erschienen in: Current Allergy and Asthma Reports 11/2023

27.10.2023

Neuromyelitis Optica: Pathogenesis Overlap with Other Autoimmune Diseases

verfasst von: Nadim Taheri, Julie Sarrand, Muhammad S. Soyfoo

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Neuromyelitis optica (NMO) is an auto-immune disease essentially depicted by optic neuritis and transverse myelitis. Per se, NMO was initially believed to be a sub-type of multiple sclerosis with typical demyelinating cerebral lesions and optic nerve inflammation. More recently, corroborating lignes of evidence have strengthened the concept of the spectrum of diseases associated with NMO and more specifically with the role of anti-aquaporin-4 antibodies in the pathogenesis of disease.

Recent Findings

In this article, we review the recent pathogenic findings in NMO and more interestingly the newly discovered role of anti-aquaporin-4 antibodies as key players in triggering cerebral lesions. The concept of spectrum of diseases associated with NMO is also discussed.

Summary

These recent findings have paved in the further understanding of the pathogenesis underlying NMO and new treatments are currently being developed targeting anti-aquaporin-4 antibodies.
Literatur
1.
Cruz RA, Chaudhary S, Guevara M, Meltzer E. Neuromyelitis optica spectrum disorders (NMOSD) and connective tissue disease (CTD): an update for the rheumatologist. Curr Rheumatol Rep. 2021;23(6):33.PubMedCrossRef
2.
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89.PubMedPubMedCentralCrossRef
3.
Wingerchuk DM, Lucchinetti CF. Neuromyelitis optica spectrum disorder. N Engl J Med. 2022;387(7):631–9.PubMedCrossRef
4.
5.
Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–12.PubMedCrossRef
6.
• Pruss H. Autoantibodies in neurological disease. Nat Rev Immunol. 2021;21(12):798–813. Article describing the inherent pathological mechanisms underlying NMO.
7.
Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268–82.PubMedCrossRef
8.
Kim SM, Kim SJ, Lee HJ, Kuroda H, Palace J, Fujihara K. Differential diagnosis of neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2017;10(7):265–89.PubMedPubMedCentralCrossRef
9.
Shahmohammadi S, Doosti R, Shahmohammadi A, Mohammadianinejad SE, Sahraian MA, Azimi AR, et al. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: a literature review. Mult Scler Relat Disord. 2019;27:350–63.PubMedCrossRef
10.
Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020;11:501.PubMedPubMedCentralCrossRef
11.
Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P, et al. Worldwide incidence and prevalence of neuromyelitis optica: a systematic review. Neurology. 2021;96(2):59–77.PubMedPubMedCentralCrossRef
12.
Hyun JW, Woodhall MR, Kim SH, Jeong IH, Kong B, Kim G, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry. 2017;88(10):811–7.PubMedCrossRef
13.
Kim KH, Kim SH, Hyun JW, Kim Y, Park H, Kim HJ. Seroprevalence of anti-myelin oligodendrocyte glycoprotein antibodies in adults with myelitis. Ann Clin Transl Neurol. 2022;9(9):1481–6.PubMedPubMedCentralCrossRef
14.
Molazadeh N, Bose G, Lotan I, Levy M. Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a systematic review. Mult Scler J Exp Transl Clin. 2022;8(4):20552173221128170.PubMedPubMedCentral
15.
Eskandarieh S, Nedjat S, Abdollahpour I, Azimi AR, Moghadasi AN, Asgari N, et al. Environmental risk factors in neuromyelitis optica spectrum disorder: a case-control study. Acta Neurol Belg. 2018;118(2):277–87.PubMedCrossRef
16.
Stiebel-Kalish H, Rubarth K, Shouchane-Blum K, Tiosano A, Lotan I, Hellmann MA, et al. Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis. Sci Rep. 2022;12(1):21312.PubMedPubMedCentralCrossRef
17.
18.
Cho EB, Yeo Y, Jung JH, Jeong SM, Han K, Yang JH, et al. Acute myocardial infarction risk in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide cohort study in South Korea. Mult Scler. 2022;28(12):1849–58.PubMedCrossRef
19.
Alvarenga MP, do Carmo LF, Vasconcelos CCF, Alvarenga MP, Alvarenga-Filho H, de Melo Bento CA, et al. Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis. Sci Rep. 2021;11(1):152.
20.
Matsushita T, Masaki K, Isobe N, Sato S, Yamamoto K, Nakamura Y, et al. Genetic factors for susceptibility to and manifestations of neuromyelitis optica. Ann Clin Transl Neurol. 2020;7(11):2082–93.PubMedPubMedCentralCrossRef
21.
Morris DL, Taylor KE, Fernando MM, Nititham J, Alarcon-Riquelme ME, Barcellos LF, et al. Unraveling multiple MHC gene associations with systemic lupus erythematosus: model choice indicates a role for HLA alleles and non-HLA genes in Europeans. Am J Hum Genet. 2012;91(5):778–93.PubMedPubMedCentralCrossRef
22.
•• Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473–7. Role of aquaporin-4 in multiple sclerosis.
23.
Pan QL, Lin FX, Liu N, Chen RC. The role of aquaporin 4 (AQP4) in spinal cord injury. Biomed Pharmacother. 2022;145: 112384.PubMedCrossRef
24.
Chang VTW, Chang HM. Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder. Neuropathol Appl Neurobiol. 2020;46(3):199–218.PubMedCrossRef
25.
Sabatino JJ Jr, Probstel AK, Zamvil SS. B cells in autoimmune and neurodegenerative central nervous system diseases. Nat Rev Neurosci. 2019;20(12):728–45.PubMedCrossRef
26.
Maciak K, Pietrasik S, Dziedzic A, Redlicka J, Saluk-Bijak J, Bijak M, et al. Th17-related cytokines as potential discriminatory markers between neuromyelitis optica (Devic’s disease) and Multiple Sclerosis-A Review. Int J Mol Sci. 2021;22(16).
27.
Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica Nat Rev Dis Primers. 2020;6(1):85.PubMedCrossRef
28.
Saadoun S, Papadopoulos MC. Role of membrane complement regulators in neuromyelitis optica. Mult Scler. 2015;21(13):1644–54.PubMedCrossRef
29.
Vourc’h P, Andres C. Oligodendrocyte myelin glycoprotein (OMgp): evolution, structure and function. Brain Res Brain Res Rev. 2004;45(2):115–24.PubMedCrossRef
30.
Ambrosius W, Michalak S, Kozubski W, Kalinowska A. Myelin Oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management. Int J Mol Sci. 2020;22(1).
31.
Takai Y, Misu T, Kaneko K, Chihara N, Narikawa K, Tsuchida S, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain. 2020;143(5):1431–46.PubMedCrossRef
32.
Devic E. Myélite aiguë dorso-lombaire avec névrite optique.-Autopsie. Congrès français de médecine. 1895;434–9.
33.
Abel A, McClelland C, Lee MS. Critical review: typical and atypical optic neuritis. Surv Ophthalmol. 2019;64(6):770–9.PubMedCrossRef
34.
Lucas S, Lalive PH, Lascano AM. Paroxysmal painful tonic spasms in neuromyelitis optica spectrum disorder. eNeurologicalSci. 2023;30:100443.
35.
Netravathi M, Saini J, Mahadevan A, Hari-Krishna B, Yadav R, Pal PK, et al. Is pruritus an indicator of aquaporin-positive neuromyelitis optica? Mult Scler. 2017;23(6):810–7.PubMedCrossRef
36.
Camara-Lemarroy CR, Burton JM. Area postrema syndrome: a short history of a pearl in demyelinating diseases. Mult Scler. 2019;25(3):325–9.PubMedCrossRef
37.
Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler. 2014;20(7):843–7.PubMedCrossRef
38.
Beigneux Y, Arnulf I, Guillaume-Jugnot P, Leu-Semenescu S, Maillart E, Lubetzki C, et al. Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;38: 101869.PubMedCrossRef
39.
Etemadifar M, Nouri H, Khorvash R, Salari M, Ghafari K, Aghababaee A. Frequency of diencephalic syndrome in NMOSD. Acta Neurol Belg. 2022;122(4):961–7.PubMedCrossRef
40.
Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler. 2015;21(7):845–53.PubMedPubMedCentralCrossRef
41.
Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, et al. Racial differences in neuromyelitis optica spectrum disorder. Neurology. 2018;91(22):e2089–99.PubMedPubMedCentralCrossRef
42.
Majed M, Fryer JP, McKeon A, Lennon VA, Pittock SJ. Clinical utility of testing AQP4-IgG in CSF: guidance for physicians. Neurol Neuroimmunol Neuroinflamm. 2016;3(3): e231.PubMedPubMedCentralCrossRef
43.
Masha N, Kimbrough DJ, Eckstein CP, Hudak NM, Skeen MB, Hartsell FL, et al. Neuromyelitis optica: clinical course and potential prognostic indicators. Mult Scler Relat Disord. 2023;69: 104414.PubMedCrossRef
44.
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805–15.PubMedCrossRef
45.
Tajfirouz DA, Bhatti MT, Chen JJ. Clinical characteristics and treatment of MOG-IgG-associated optic neuritis. Curr Neurol Neurosci Rep. 2019;19(12):100.PubMedCrossRef
46.
Du Q, Shi Z, Chen H, Zhang Y, Wang J, Qiu Y, et al. Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders. J Neuroimmunol. 2021;353: 577494.PubMedCrossRef
47.
Iyer A, Elsone L, Appleton R, Jacob A. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity. 2014;47(3):154–61.PubMedCrossRef
48.
Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65(1):78–83.PubMedCrossRef
49.
Wang X, Shi Z, Zhao Z, Chen H, Lang Y, Kong L, et al. The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases. Front Immunol. 2022;13: 959469.PubMedPubMedCentralCrossRef
50.
Pache F, Ringelstein M, Aktas O, Kleiter I, Jarius S, Siebert N, et al. C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD. J Neuroimmunol. 2021;360: 577699.PubMedCrossRef
51.
Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler. 2012;18(1):5–10.PubMedCrossRef
52.
Zhang B, Zhong Y, Wang Y, Dai Y, Qiu W, Zhang L, et al. Neuromyelitis optica spectrum disorders without and with autoimmune diseases. BMC Neurol. 2014;14:162.PubMedPubMedCentralCrossRef
53.
Carnero Contentti E, Lopez PA, Pettinicchi JP, Tkachuk V, Daccach Marques V, de Castillo IS, et al. Neuromyelitis optica spectrum disorders with and without associated autoimmune diseases. Neurol Sci. 2023;44(5):1731–7.PubMedCrossRef
54.
Alvarez MR, Gurung A, Velayndhan V, Cuascut F, Alkabie S, Freeman L, et al. Predictors of overlapping autoimmune disease in Neuromyelitis Optica Spectrum disorder (NMOSD): a retrospective analysis in two inner-city hospitals. J Neurol Sci. 2022;443: 120460.PubMedCrossRef
55.
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European league against rheumatism/american college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400–12.PubMedPubMedCentralCrossRef
56.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599–608.
57.
Williams JN, Speyer CB, Kreps DJ, Kimbrough DJ, Costenbader K, Bhattacharyya S. Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. Lupus. 2019;28(14):1656–62.PubMedPubMedCentralCrossRef
58.
Tavor Y, Herskovitz M, Ronen G, Balbir-Gurman A. Longitudinally extensive transverse myelitis in a lupus-neuromyelitis optica overlap. Rambam Maimonides Med J. 2021;12(1).
59.
Asgari N, Jarius S, Laustrup H, Skejoe HP, Lillevang ST, Weinshenker BG, et al. Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: a predominantly population-based study. Mult Scler. 2018;24(3):331–9.PubMedCrossRef
60.
Zhang S, Wang Z, Zhao J, Wu DI, Li J, Wang Q, et al. Clinical features of transverse myelitis associated with systemic lupus erythematosus. Lupus. 2020;29(4):389–97.PubMedCrossRef
61.
Ochi MGS, Shapiro SC, Melamed E. Lupus and NMOSD: the blending of humoral autoimmunity. Case Rep Rheumatol. 2020;2020:8820071.PubMedPubMedCentral
62.
Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League against rheumatism classification criteria for primary sjogren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35–45.PubMedCrossRef
63.
Carvalho DC, Tironi TS, Freitas DS, Kleinpaul R, Talim NC, Lana-Peixoto MA. Sjogren syndrome and neuromyelitis optica spectrum disorder co-exist in a common autoimmune milieu. Arq Neuropsiquiatr. 2014;72(8):619–24.PubMedCrossRef
64.
Tristano AG. A case of Sjogren’s syndrome with acute transverse myelitis and polyneuropathy in a patient free of sicca symptoms. Clin Rheumatol. 2006;25(1):113–4.PubMedCrossRef
65.
Manabe Y, Sasaki C, Warita H, Hayashi T, Shiro Y, Sakai K, et al. Sjogren’s syndrome with acute transverse myelopathy as the initial manifestation. J Neurol Sci. 2000;176(2):158–61.PubMedCrossRef
66.
Kahlenberg JM. Neuromyelitis optica spectrum disorder as an initial presentation of primary Sjogren’s syndrome. Semin Arthritis Rheum. 2011;40(4):343–8.PubMedCrossRef
67.
Akaishi T, Takahashi T, Fujihara K, Misu T, Fujimori J, Takai Y, et al. Impact of comorbid Sjogren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol. 2021;268(5):1938–44.PubMedCrossRef
68.
Lin L, Hang H, Zhang J, Lu J, Chen D, Shi J. Clinical significance of anti-SSA/Ro antibody in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2022;58: 103494.PubMedCrossRef
69.
Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114–22.PubMedPubMedCentralCrossRef
70.
Uzawa A, Mori M, Iwai Y, Kobayashi M, Hayakawa S, Kawaguchi N, et al. Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis. J Neurol Sci. 2009;287(1–2):105–7.PubMedCrossRef
71.
Leite MI, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology. 2012;78(20):1601–7.PubMedPubMedCentralCrossRef
72.
73.
Dodig D, Genge A, Selchen D, Freedman MS. Complement inhibition in myasthenia gravis and neuromyelitis optica spectrum disorder. Can J Neurol Sci. 2023;50(2):165–73.PubMedCrossRef
74.
75.
Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223–43.PubMedCrossRef
76.
Nagaishi A, Takagi M, Umemura A, Tanaka M, Kitagawa Y, Matsui M, et al. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry. 2011;82(12):1360–4.PubMedCrossRef
77.
Li H, Dai Y, Wu AM, Sun X, Lin Y, Lv K, et al. Anti-thyroid antibodies and cerebrospinal fluid findings in neuromyelitis optica spectrum disorders. J Neuroimmunol. 2015;281:38–43.PubMedCrossRef
78.
Jarius S, Aktas O, Ayzenberg I, Bellmann-Strobl J, Berthele A, Giglhuber K, et al. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol. 2023;270(7):3341–68.
79.
Takai Y, Kuroda H, Misu T, Akaishi T, Nakashima I, Takahashi T, et al. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Mult Scler Relat Disord. 2021;49: 102750.PubMedCrossRef
80.
Demuth S, Guillaume M, Bourre B, Ciron J, Zephir H, Sirejacob Y, et al. Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. J Neuroinflammation. 2022;19(1):62.PubMedPubMedCentralCrossRef
81.
Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014;20(4):501–4.PubMedCrossRef
82.
Lin J, Xue B, Zhu R, Pan J, Li J, Lin Y, et al. Intravenous immunoglobulin as the rescue treatment in NMOSD patients. Neurol Sci. 2021;42(9):3857–63.PubMedCrossRef
83.
Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298–306. (Treatment of NMO with rituximab).
84.
Magdalena C, Clarissa A, Sutandi N. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder treated with rituximab, azathioprine, and mycophenolate mofetil: a systematic review and meta-analysis. Innov Clin Neurosci. 2022;19(4–6):51–64.PubMedPubMedCentral
85.
Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443–8. (Treatment of NMO with rituximab).
86.
Bosch X, Saiz A, Ramos-Casals M, Group BS. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol. 2011;7(3):165–72.CrossRef
Metadaten
Titel
Neuromyelitis Optica: Pathogenesis Overlap with Other Autoimmune Diseases
verfasst von
Nadim Taheri
Julie Sarrand
Muhammad S. Soyfoo
Publikationsdatum
27.10.2023
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 11/2023
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-023-01112-y

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise